Vašíček Jaromír, Bauer Miroslav, Kontseková Eva, Baláži Andrej, Svoradová Andrea, Dujíčková Linda, Tvrdá Eva, Vozaf Jakub, Supuka Peter, Chrenek Peter
NPPC-Research Institute for Animal Production Nitra, Hlohovecká 2, 951 41 Lužianky, Slovakia.
Institute of Biotechnology, Faculty of Biotechnology and Food Science, Slovak University of Agriculture in Nitra, Tr. A. Hlinku 2, 949 76 Nitra, Slovakia.
Biomolecules. 2025 Jul 15;15(7):1021. doi: 10.3390/biom15071021.
The rabbit is a widely used experimental model for human translational research and stem cell therapy. Many studies have focused on rabbit mesenchymal stem cells from different biological sources for their possible application in regenerative medicine. However, a minimal number of studies have been published aimed at rabbit hematopoietic stem/progenitor cells, mainly due to the lack of specific anti-rabbit CD34 antibodies. In general, CD34 antigen is commonly used to identify and isolate hematopoietic stem/progenitor cells in humans and other animal species. The aim of this study was to develop novel monoclonal antibodies highly specific to rabbit CD34 antigen. We used hybridoma technology, two synthetic peptides derived from predicted rabbit CD34 protein, and a recombinant rabbit CD34 protein as immunogens to produce monoclonal antibodies (mAbs) specific to rabbit CD34. The produced antibodies were screened for their binding activity and specificity using ELISA, flow cytometry, and Western blot analysis. Finally, four mAbs (58/47/26, 58/47/34, 182/7/80, and 575/36/8) were selected for the final purification process. The purified mAbs recognized up to 2-3% of total rabbit bone marrow cells, while about 2% of those cells exhibited CD45 expression, which are likely rabbit primitive hematopoietic stem cells and their hematopoietic progenitors, respectively. The newly generated and purified mAbs specifically recognize CD34 antigen in rabbit bone marrow or peripheral blood and can be therefore used for further immunological applications, to study rabbit hematopoiesis or to establish a new animal model for hematopoietic stem cell transplantation studies.
兔子是人类转化研究和干细胞治疗中广泛使用的实验模型。许多研究聚焦于来自不同生物来源的兔子间充质干细胞,探讨其在再生医学中的潜在应用。然而,针对兔子造血干细胞/祖细胞的研究发表数量极少,主要原因是缺乏特异性抗兔CD34抗体。一般来说,CD34抗原常用于鉴定和分离人类及其他动物物种的造血干细胞/祖细胞。本研究的目的是开发对兔CD34抗原具有高度特异性的新型单克隆抗体。我们利用杂交瘤技术,以两条源自预测的兔CD34蛋白的合成肽和重组兔CD34蛋白作为免疫原,来制备针对兔CD34的单克隆抗体(mAbs)。使用酶联免疫吸附测定(ELISA)、流式细胞术和蛋白质免疫印迹分析对所产生的抗体进行结合活性和特异性筛选。最后,选择了四种单克隆抗体(58/47/26、58/47/34、182/7/80和575/36/8)进行最终纯化。纯化后的单克隆抗体识别高达2 - 3%的兔骨髓细胞总数,而这些细胞中约2%表达CD45,分别可能是兔原始造血干细胞及其造血祖细胞。新产生并纯化的单克隆抗体可特异性识别兔骨髓或外周血中的CD34抗原,因此可用于进一步的免疫学应用,研究兔子的造血过程或建立用于造血干细胞移植研究的新动物模型。